Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Nitrosamines Problems Are More Widespread in Drugs Than FDA Anticipated: Report The EU and Canada have set daily acceptable limits for all nitrosamines, but the FDA has not. During a meeting this week the U.S. regulators met to discuss how to bets address the problem with nitrosames in drugs. November 1, 2022 Irvin Jackson Add Your Comments Federal regulators met with generic drug manufacturers on Monday, to discuss the growing problem with nitrosamines, which are cancer-causing chemicals that can be a byproduct of the drug manufacturing process. The U.S. Food and Drug Administration (FDA) first raised concerns about nitrosamines, specifically nitrosodimethylamine (NDMA), when valsartan recalls were first announced in 2018, after generic versions of the hypertension drug were found to contain unsafe levels of the human carcinogen. However, as regulators and drug manufacturers became more aware of nitrosames in drug products and the potential cancer risks, they have been found in a number of other drugs, including Chantix, Metformin and Zantac. This has led to numerous recalls and litigation, including more than 100,000 Zantac cancer lawsuits currently begin filed against manufacturers of the heartburn drug. ZANTAC LAWSUITS Did you or a loved one take recalled Zantac? Side effects of Zantac may increase the risk of cancer, due to chemical impurities found in the heartburn drug. Learn More SEE IF YOU QUALIFY FOR COMPENSATION ZANTAC LAWSUITS Did you or a loved one take recalled Zantac? Side effects of Zantac may increase the risk of cancer, due to chemical impurities found in the heartburn drug. Learn More SEE IF YOU QUALIFY FOR COMPENSATION In response to the growing problem, the FDA issued new guidance in 2020 on how to detect and prevent nitrosamine impurities, which set daily acceptable limits for six different nitrosamines, including NDMA. The guidance was passed on the belief that the problem would be small, but the FDA underestimated the scope of the problem. According to a report published in Regulatory Focus on Monday, hundreds of drugs turned out to have nitrosamines, many of them not on the list impacted by the FDA guidance. Regulators are now discovering that any drug with an active ingredient that includes a vulnerable amine, a type of nitrogen molecule usually derived from ammonia, could have nitrosamine contamination caused during the manufacturing process. That includes drugs such as angiotensin-converting enzyme (ACE) inhibitors used in hypertension drugs; beta blockers in many heart drugs, and selective serotonin reuptake inhibitors (SSRIs), which are commonly used antidepressants. Under the weight of the recalls, the 2020 guidance quickly became outdated, and now the FDA is trying to decide about all the other nitrosamines they keep discovering in commonly used drugs. In the European Union and Canada, regulators have set daily acceptable limits for novel nitrosamines, which have not been fully researched as a precaution. The FDA has not. On Monday, agency officials met with the Association for Accessible Medicines (AAM), a lobbying group for generic drug manufacturers to discuss how to move forward and whether the U.S. should have similar wide-sweeping, daily acceptable limits for all nitrosamines; even if they do not know whether they present a health risk to patients. FDA officials have also held science workshops, and are reportedly talking to other stakeholders about how to address the nitrosamine problem. It is expected that the agency will update the guidance and some point, but it is unclear whether the FDA will set daily limits for all nitrosamines as a safety precaution. November 2022 Zantac Lawsuit Update Most of the litigation resulting from the nitrosamine recalls has been focused on Zantac (ranitidine), which was used by millions of Americans for treatment of heartburn and acid reflux, before it was removed from the market in late 2019 due to the presence of NDMA. GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Sanofi and various other manufacturers, distributors and retailers involved in the sale of brand name or generic ranitidine pills now face more than 100,000 Zantac lawsuits brought by former users who indicate they have been diagnosed with bladder cancer, esophageal cancer, liver cancer, pancreatic cancer, stomach cancer or other injuries, as NDMA moved through their body. Given common questions of fact and law raised in litigation brought throughout the federal court system, centralized pretrial proceedings have been established in a federal MDL before U.S. District Judge Robin L. Rosenberg in the Southern District of Florida, who has been presiding over coordinated discovery and a “bellwether” process where a small group of cases are being prepared for early trial dates. There are also cases filed in state courts as well. In California state court, a series of four Zantac lawsuits have been scheduled for trial next year, with cases scheduled to go before different juries on February 13, 2023, May 1, 2023, August 7, 2023 and October 23, 2023. These trials will be closely watched by parties involved in the litigation, and may provide a “bellwether” to help gauge how juries will respond to certain evidence and testimony that will be repeated throughout the litigation. If plaintiffs are successful, it is likely to drive up the cost of any Zantac settlements the drug makers will offer to avoid tens of thousands of individual cases going to trial nationwide in the coming years. Tags: Cancer, Chantix, Chemicals, FDA, Generic Drug, Metformin, NDMA, Nitrosamines, Valsartan, Zantac More Zantac Lawsuit Stories Jury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim February 5, 2025 Zantac Bladder Cancer Lawsuit Trial Ends With Hung Jury in California November 22, 2024 GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers October 10, 2024 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: yesterday) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025) Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 2 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025) BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 3 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)
GSK To Pay $2.2 Billion To Settle Zantac Cancer Lawsuits Brought by 80,000 Consumers October 10, 2024
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: yesterday) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 2 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 3 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)